Florida-based biopharmaceutical company Oragenics, Inc. (OTCBB: ORNI) (
) has announced that its oral care probiotic for pets,
), will join the diverse array of pet products available to pet stores small and large in Canada through Rolf C. Hagen Inc.
“There is a strong synergy with Hagen’s extensive market penetration throughout Canada, which will be complemented by the new technology of
probiotics for pets’ oral care,” said Gerry David, Executive Vice President, Sales and Marketing for Oragenics.
“We are excited to have the opportunity to introduce this new innovation in oral care from Oragenics to our retail partners, who are continuously on the lookout for new and exciting health products to offer their customers,” said Scott Lyall, National Sales Manager / Directeur National des Ventes.
ProBiora3®, the active ingredient in Oragenics' probiotic products, naturally supports gum and tooth health while freshening breath and whitening teeth. ProBiora3® technology was developed by Oragenics' Chief Scientific Officer, Dr. Jeffrey Hillman, D.M.D., Ph.D., during more than 25 years of research, which began at the Harvard-affiliated Forsyth Institute in Boston and continued at the University of Florida. This technology has only recently become available to the general public. ProBiora3® contains three strains of beneficial bacteria that help maintain a healthy microbial balance in the mouth. It is 100% natural and is made in the USA in an FDA-registered and GMP-certified facility.
About Oragenics, Inc.
Oragenics is a biopharmaceutical company focused primarily on oral health products and novel antibiotics. Within oral health, Oragenics is developing its pharmaceutical product candidate, SMaRT Replacement Therapy, and also commercializing its oral probiotic product, ProBiora3. Within antibiotics, Oragenics is developing a pharmaceutical candidate, MU1140-S and intends to use its patented, novel organic chemistry platform to create additional antibiotics for therapeutic use.